Engh RA - Search Results

1

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.

Kancha RK, von Bubnoff N, Bartosch N, Peschel C, Engh RA, Duyster J. Kancha RK, et al. Among authors: engh ra. PLoS One. 2011;6(10):e26760. doi: 10.1371/journal.pone.0026760. Epub 2011 Oct 28. PLoS One. 2011. PMID: 22046346 Free PMC article.

2

Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells.

Illert AL, Seitz AK, Rummelt C, Kreutmair S, Engh RA, Goodstal S, Peschel C, Duyster J, von Bubnoff N. Illert AL, et al. Among authors: engh ra. PLoS One. 2014 Nov 26;9(11):e112318. doi: 10.1371/journal.pone.0112318. eCollection 2014. PLoS One. 2014. PMID: 25426931 Free PMC article.

3

The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.

von Bubnoff N, Gorantla SP, Engh RA, Oliveira TM, Thöne S, Aberg E, Peschel C, Duyster J. von Bubnoff N, et al. Among authors: engh ra. Oncogene. 2011 Feb 24;30(8):933-43. doi: 10.1038/onc.2010.476. Epub 2010 Oct 25. Oncogene. 2011. PMID: 20972453

4

FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.

von Bubnoff N, Engh RA, Aberg E, Sänger J, Peschel C, Duyster J. von Bubnoff N, et al. Among authors: engh ra. Cancer Res. 2009 Apr 1;69(7):3032-41. doi: 10.1158/0008-5472.CAN-08-2923. Epub 2009 Mar 24. Cancer Res. 2009. PMID: 19318574

5

The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A-PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine.

Alexeeva M, Åberg E, Engh RA, Rothweiler U. Alexeeva M, et al. Among authors: engh ra. Acta Crystallogr D Biol Crystallogr. 2015 May;71(Pt 5):1207-15. doi: 10.1107/S1399004715005106. Epub 2015 Apr 25. Acta Crystallogr D Biol Crystallogr. 2015. PMID: 25945585

6

Structural origins of AGC protein kinase inhibitor selectivities: PKA as a drug discovery tool.

Åberg E, Lund B, Pflug A, Gani OA, Rothweiler U, de Oliveira TM, Engh RA. Åberg E, et al. Among authors: engh ra. Biol Chem. 2012 Oct;393(10):1121-9. doi: 10.1515/hsz-2012-0248. Biol Chem. 2012. PMID: 23092797 Review.

7

Evaluating the predictivity of virtual screening for ABL kinase inhibitors to hinder drug resistance.

Gani OA, Narayanan D, Engh RA. Gani OA, et al. Among authors: engh ra. Chem Biol Drug Des. 2013 Nov;82(5):506-19. doi: 10.1111/cbdd.12170. Epub 2013 Oct 1. Chem Biol Drug Des. 2013. PMID: 23746052 Free PMC article.

8

Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy.

Woywod C, Gruber FX, Engh RA, Flå T. Woywod C, et al. Among authors: engh ra. PLoS One. 2017 Jul 5;12(7):e0179700. doi: 10.1371/journal.pone.0179700. eCollection 2017. PLoS One. 2017. PMID: 28678800 Free PMC article.

9

p38α MAP kinase dimers with swapped activation segments and a novel catalytic loop conformation.

Rothweiler U, Åberg E, Johnson KA, Hansen TE, Jørgensen JB, Engh RA. Rothweiler U, et al. Among authors: engh ra. J Mol Biol. 2011 Aug 12;411(2):474-85. doi: 10.1016/j.jmb.2011.06.013. Epub 2011 Jun 15. J Mol Biol. 2011. PMID: 21699901

10

Mutants of protein kinase A that mimic the ATP-binding site of Aurora kinase.

Pflug A, de Oliveira TM, Bossemeyer D, Engh RA. Pflug A, et al. Among authors: engh ra. Biochem J. 2011 Nov 15;440(1):85-93. doi: 10.1042/BJ20110592. Biochem J. 2011. PMID: 21774789

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

91 results

Search Page